Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AR | P10275 | 6/20 | 0.49 |
| ▸ | CDK1 | P06493 | 9/20 | 0.40 |
| ▸ | ABCG2 | Q9UNQ0 | 2/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.40 |
| ▸ | ABCC3 | O15438 | 1/20 | 0.39 |
| ▸ | ESR1 | P03372 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | PGR | P06401 | 1/20 | 0.39 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.39 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.39 |
| ▸ | DRD1 | P21728 | 1/20 | 0.39 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.39 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.39 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.39 |
| ▸ | ABCC1 | P33527 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11936715 | 0.83 | CDK1 (0.39) | CDK1ABCG2CYP2C9CYP2C19ABCC3 | |
| SCHEMBL11936687 | 0.83 | CYP2C9 (0.56) | ABCG2CYP2C9CYP2C19ABCC3ESR1 | |
| SCHEMBL11936714 | 0.81 | SLC2A1 (0.44) | ABCG2CYP2C9CYP2C19ABCC3ESR1 | |
| SCHEMBL11936716 | 0.81 | IDH2 (0.47) | ABCG2CYP2C19CYP1A2CYP3A4 | |
| SCHEMBL11936712 | 0.80 | CYP2C9 (0.39) | CDK1ABCG2CYP2C9CYP2C19ABCC3 | |
| SCHEMBL11936705 | 0.78 | CYP2C9 (0.62) | ABCG2CYP2C9CYP2C19ABCC3ESR1 | |
| SCHEMBL11936713 | 0.77 | CDK2 (0.42) | CDK1ABCG2CYP2C9CYP2C19ABCC3 | |
| SCHEMBL12092566 | 0.76 | CYP2C9 (0.48) | ABCG2CYP2C9CYP2C19ABCC3ESR1 | |
| SCHEMBL11936697 | 0.74 | NPC1 (0.46) | CDK1ABCG2CYP2C9CYP2C19ABCC3 | |
| SCHEMBL11936719 | 0.74 | KCNH2 (0.38) | CDK1ABCG2CYP2C9CYP2C19ABCC3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8354532-B2 | Pyrrolo [2,3-D] pyrimidines as non-nucleoside reverse transcriptase inhibitors for treatment of HIV | ARDEA BIOSCIENCES, INC. (US) | 2013-01-15 | — | — | US | disclosed |
| US-8354532-B2 | Pyrrolo [2,3-D] pyrimidines as non-nucleoside reverse transcriptase inhibitors for treatment of HIV | ARDEA BIOSCIENCES, INC. (US) | 2013-01-15 | — | — | US | disclosed |
| US-20120226037-A1 | PYRROLO [2,3-D] PYRIMIDINES AS NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS FOR TREATMENT OF HIV | ARDEA BIOSCIENCES, INC. (US) | 2012-09-06 | — | — | US | disclosed |
| US-20120226037-A1 | PYRROLO [2,3-D] PYRIMIDINES AS NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS FOR TREATMENT OF HIV | ARDEA BIOSCIENCES, INC. (US) | 2012-09-06 | — | — | US | disclosed |
| US-8227601-B2 | Diaryl-purines, azapurines and -deazapurines as non-nucleoside reverse transcriptase inhibitor for treatment of HIV | ARDEA BIOSCIENCES, INC. (US) | 2012-07-24 | — | — | US | disclosed |
| US-8227601-B2 | Diaryl-purines, azapurines and -deazapurines as non-nucleoside reverse transcriptase inhibitor for treatment of HIV | ARDEA BIOSCIENCES, INC. (US) | 2012-07-24 | — | — | US | disclosed |
| US-20090124802-A1 | Diaryl-purines, azapurines and -deazapurines as non-nucleoside reverse transcriptase inhibitor for treatment of hiv | INTRABIOTICS PHARMACEUTICALS, INC. | 2009-05-14 | — | — | US | disclosed |
| US-20090124802-A1 | Diaryl-purines, azapurines and -deazapurines as non-nucleoside reverse transcriptase inhibitor for treatment of hiv | INTRABIOTICS PHARMACEUTICALS, INC. | 2009-05-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120226037-A1 | PYRROLO [2,3-D] PYRIMIDINES AS NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS FOR TREATMENT OF HIV | TYMP, TPMT, PNP | AR 3766/4885CDK1 1274/4885ABCG2 746/4885 |
| US-20090124802-A1 | Diaryl-purines, azapurines and -deazapurines as non-nucleoside reverse transcriptase inhibitor for treatment of hiv | PNP, TPMT, DUT | AR 3201/4885CDK1 1102/4885ABCG2 771/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.